PORTIONS HEREIN IDENTIFIED BY [***] HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND RESTATED AGREEMENTPatent Assignment Agreement • February 28th, 2024 • Amicus Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This SECOND RESTATED AGREEMENT (the “Agreement”) is made as of the 19th day of November, 2013 (the “Second Restated Effective Date”) by and between Amicus Therapeutics, Inc., a Delaware corporation having a place of business at 1 Cedar Brook Drive, Cranbury, New Jersey, 08512 (“Amicus”) and Glaxo Group Limited, a company organized under the laws of England and Wales with its registered office address at 980 Great West Road, Brentford, Middlesex,TW8 9GS, England (“GSK”). Amicus and GSK are each referred to herein by name or as a “Party” or, collectively, as the “Parties”.
